Dilazep dihydrochloride

Dilazep dihydrochloride Structure
Dilazep dihydrochloride structure
Common Name Dilazep dihydrochloride
CAS Number 20153-98-4 Molecular Weight 677.61000
Density N/A Boiling Point 646ºC at 760 mmHg
Molecular Formula C31H46Cl2N2O10 Melting Point N/A
MSDS Chinese USA Flash Point 344.5ºC
Symbol GHS07
GHS07
Signal Word Warning

Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta.

Biochem. J. 328 , 739, (1997)

Mammalian equilibrative nucleoside transporters are typically divided into two classes, es and ei, based on their sensitivity or resistance respectively to inhibition by nitrobenzylthioinosine (NBMPR). Previously, we have reported the isolation of a cDNA clon...

Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism.

J. Pharmacol. Exp. Ther. 285 , 568, (1998)

Selective inhibitors of adenosine production, degradation and transport were used to potentiate in vivo levels of adenosine and to determine the source of both basal and N-methyl-D-aspartate (NMDA)-induced increases in levels of endogenous adenosine in vivo. ...

Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes.

Blood 90 , 2345-2356, (1997)

Dilazep, an antiplatelet agent, is generally used as an antithrombotic drug in clinical practice. Dilazep is also known to exert cytoprotective and antioxidant effects on endothelial cells. However, its effect on the endothelial or monocyte procoagulant activ...

Incidence and prognosis of systemic lupus erythematosus in a 35 year period in Fukushima, Japan.

Pediatr. Int. 57 , 650-5, (2015)

We examined the epidemiology, clinical manifestations, and prognosis of pediatric systemic lupus erythematosus (SLE) in Fukushima Prefecture, Japan over a 35 year period.We collected the medical records of 37 patients diagnosed with SLE between 1977 and 2013....